Public trading strategy
Eli Lilly's next-gen weight-loss drug crushes it in trials — load up on obesity
Thesis
The weight-loss drug market is turning into a gold rush, and Eli Lilly just proved it has the scientific firepower to stay at the very top of the industry. This successful trial clears a massive hurdle, practically guaranteeing a new blockbuster product that will generate billions in revenue. As the positive news lifts the entire sector, buying Lilly and its closest competitors offers a way to profit from a massive, long-term shift in global healthcare demand.
Strategy approach
Build a rule-based strategy that enters long LLY, AMGN, and NVO on the daily (D1) timeframe. Entry condition: RSI(14) is between 50 and 70, and MACD line crosses above the signal line. Exit condition: RSI(14) exceeds 80, or a 4% trailing stop is hit, with a 15-day max hold.